Key Highlights

  • Vitasora Health Limited (ASX:VHL) shares were down 11.54% at $0.012 during the 22 October 2026 trading session, while the S&P/ASX 200 was down 0.44%.
  • In its announcement dated 6 October 2026, the company estimated September quarter Revenue of US$1,028K, up 38% on the June quarter.
  • The company reported 32 productive Care Coordinators and 39 employed, with recruitment directed toward 115 by Q1 2027.

Vitasora Health Limited (ASX:VHL) shares were down 11.54% at $0.012 during the Trading session on 22 October 2026, while the S&P/ASX 200 stood at 8,792.20, down 0.44%, and the All Ordinaries stood at 8,916.20, down 0.45%. Vitasora provides remote patient monitoring and chronic care management services to healthcare providers in the United States. In an announcement dated 6 October 2026, the company released an October 2026 market update and investor presentation covering care coordinator capacity, estimated revenue and its path to operational break-even.

About the Company

Vitasora Health Limited is listed on the Australian Securities Exchange under the code VHL, and its shares also trade on the OTCQB under the code VHLUF. The company is headquartered in Melbourne, Victoria, with offices in Los Angeles. Marjan Mikel is CEO and Managing Director, and Nicholas Smedley is Non-Executive Chairman.

The company describes itself as providing digital connected care in the US healthcare market.

Business Overview

Vitasora's remote patient monitoring (RPM) and chronic care management (CCM) services are aimed at helping healthcare clients operate under value-based care arrangements. The company also offers connected care management programs for chronic conditions, including remote wheeze detection for respiratory disorders.

The wheezo device is described as a Class II medical device approved by the US Food and Drug Administration. It analyses breath sounds for wheeze and works with the respiri app, which lets users log symptoms and triggers. Vitasora's care platform, vCare, integrates with electronic medical records and was launched on 1 April 2026.

Revenue and Capacity Update

In its announcement dated 6 October 2026, Vitasora estimated September quarter revenue at US$1,028K, including other revenue, which was 38% higher than the June quarter's US$745K, or 24% higher excluding a US$105K one-off. The company noted that these are unaudited management estimates, are non-IFRS measures and may differ materially from accounting revenue.

Care Coordinator utilisation was 88.5% at the September exit across all care types, against a 95% objective. CCM-program care minutes reached 339K in the September quarter, up 44% from 236K in the June quarter. The September exit rate was estimated at about US$17.4K a day, which the company described as illustrative rather than a forecast.

Staffing Plans and Patient Metrics

The company reported 32 productive Care Coordinators, with 39 employed including those in training. It plans 48 by late Q4 2026 and has dedicated recruitment directed toward 115 by Q1 2027, which it defined as January to March 2027.

Sept quarter enrolment activity was 1,596, equal to a pace of 2,388 a quarter at the September rate. Care intensity was estimated at about 2.1 care billing codes per qualifying patient, against a planning assumption of about 2. The company also cited an observational study at one partner practice, in which 303 of 435 patients ended below 140 systolic blood pressure.

Related Sector Context

Remote patient monitoring and chronic care management form part of the digital health segment. In the US, parts of the activity are billed through Medicare codes tied to time spent on care, so staffing levels and utilisation are linked to billable minutes.

On 22 October 2026, the S&P/ASX 200 was down 0.44% and the All Ordinaries was down 0.45% during the trading session. Vitasora's fall of 11.54% was larger than both benchmark moves.

Risks to Weigh In

The company's forward-looking statements note risks inherent in developing technology and building a Business around products and services, and say actual results could differ materially. The presentation's revenue figures from April 2026 are management estimates that remain subject to reconciliation with invoicing and the September quarter Appendix 4C.

The company also stated that exit rates and capacity scenarios are illustrative and not forecasts. Its operational break-even measure covers US operating costs before Australian corporate costs and excludes a UPEC contract shortfall, and is distinct from the monthly Cash Flow break-even target in its Appendix 4C. The patient outcome data come from one practice, with no comparison group.

Catalysts on Watch

The update lists adding productive Care Coordinators, enrolling existing patients, launching new clients, lifting value per patient and addressing the UPEC contract shortfall with added contracted Volume as the next phase. The company said the aim is to lift the daily rate and sustain it for a full month to reach operational break-even.

Staffing milestones include 48 Care Coordinators by late Q4 2026 and the recruitment capability directed toward 115 by Q1 2027. The company said the estimates remain subject to reconciliation with the September quarter Appendix 4C.

Putting It Together

Vitasora Health shares were trading lower on 22 October 2026 in a market that was also lower. The company's announcement dated 6 October 2026 set out estimated September quarter revenue of US$1,028K, staffing and utilisation figures, and its stated steps toward operational break-even, with the revenue numbers remaining unaudited estimates.